Barclays
SUPN icon

Barclays’s Supernus Pharmaceuticals SUPN Stock Holding History

Barclays’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,700
Closed -$89K – 7107
2019
Q2 		$89K Sell
2,700
-2,400
-47% -$82.2K ﹤0.01% 5770
2019
Q1 		$179K Buy
5,100
+2,700
+113% +$100K ﹤0.01% 4903
2018
Q4 		$80K Buy
+2,400
New +$103K ﹤0.01% 5200
2017
Q4 		– Sell
-200
Closed -$8K – 7102
2017
Q3 		$8K Buy
+200
New +$8.65K ﹤0.01% 6241

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Barclays's SUPN Position: Q2 2026 in Review

Barclays reduced its Supernus Pharmaceuticals (SUPN) stake by 67% in Q2 2026, selling an estimated $3.53M and leaving 35,634 shares worth $1.66M. The position accounts for ﹤0.01% of the portfolio, ranked #2457.

Barclays first reported a position in SUPN in Q2 2013 and has held it in 53 quarters since. The position peaked at $11M in Q3 2025. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Barclays held 35,634 shares of Supernus Pharmaceuticals worth $1.66M as of Q2 2026.
  • Barclays sold 73,480 Supernus Pharmaceuticals shares in Q2 2026, an estimated $3.53M.
  • Supernus Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2457 holding.
  • Barclays first reported a position in Supernus Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Barclays's Supernus Pharmaceuticals position peaked at $11M in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.